Affimed N.V. (AFMD)

$0.18 -0.10 (-34.95%)
Market Cap 2.92M
Revenue (ttm) 8.96M
Net Income (ttm) -114.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,279.69%
Debt to Equity Ratio 0.47
Volume 23,468,002
Avg Vol 19,511,936
Day's Range N/A - N/A
Shares Out 16.10M
Stochastic %K 15%
Beta 2.07
Analysts Sell
Price Target $6.83

Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 621 560030
Fax: 49 621 56003 649
Address:
Gottlieb-Daimler-Straße 2, Mannheim, Germany
deathknight
deathknight Dec. 5 at 7:02 PM
$AFMD Heard that this board is closed. Is this why no new post since Tuesday?
2 · Reply
Think_Bigly
Think_Bigly Dec. 5 at 2:10 AM
$AFMD mobile app.
0 · Reply
Think_Bigly
Think_Bigly Dec. 3 at 4:59 AM
$AFMD buying will resurge the day it opens, bcoz the smart trades got out early, and they're looking for an entry. The stock isn't going any lower.. imo.
1 · Reply
SRT2019
SRT2019 Dec. 3 at 4:07 AM
$AFMD Glide has updated Affimed logo on their website.
1 · Reply
Think_Bigly
Think_Bigly Dec. 1 at 1:02 AM
$AFMD RMAT designation will accelerate development and save 'the developer' ~$100M in development costs. https://www.biospace.com/press-releases/affimed-announces-acimtamig-and-allonk-combination-granted-regenerative-medicine-advanced-therapy-rmat-designation-by-the-u-s-food-and-drug-administration-fda
0 · Reply
Think_Bigly
Think_Bigly Nov. 30 at 6:05 PM
$AFMD Timing: buyers will return 30 in days. Generally, a wash sale has three parts. An investor notices they are in a losing position, so they close it by selling the stock or exiting a trading position. The sale allows them to take a loss that they can legally claim on their tax returns as a reduction of their earnings for that year, which reduces their total tax liability. The investor will look to purchase the security at or below the price at which they sold it—if the purchase occurred 30 days before or after the sale, it is considered a wash sale, and the loss cannot be claimed. https://www.investopedia.com/terms/w/washsale.asp
0 · Reply
caradhras36
caradhras36 Nov. 28 at 7:38 PM
$AFMD If there are any plans of changing the fate of this stock by institutions or capital investment firms, I would do it after new year when people sell it for tax loss. I don’t expect anything before new year’s. That’s the game theoretical approach.
0 · Reply
Think_Bigly
Think_Bigly Nov. 27 at 4:39 AM
$AFMD RMAT designation provides several benefits, including all the advantages of the Fast Track and Breakthrough Therapy designations, such as early and frequent interactions with the FDA to facilitate accelerated approval. It allows for accelerated approval based on surrogate or intermediate endpoints—biomarkers that substitute for direct clinical benefits—enabling earlier market access for promising therapies.
0 · Reply
Think_Bigly
Think_Bigly Nov. 27 at 4:26 AM
$AFMD Abstract - In March 2017, the US FDA introduced the new Regenerative Medicine Advanced Therapy (RMAT) designation thus recognizing the enormous potential of these medicines and the need for efficient regulatory tools to accelerate their development and their commercial availability. https://pubmed.ncbi.nlm.nih.gov/29895180/
0 · Reply
Think_Bigly
Think_Bigly Nov. 27 at 12:47 AM
$AFMD Solid tumor market is 2-3x greater than Hodgkins disease. -This promising combination has applicability not only in HL, but also in CD30 positive lymphomas such as peripheral T-cell lymphoma (PTCL), which can also be resistant to conventional therapies, has a high risk of relapse, and where few products are approved. Generating clinical proof-of-concept in PTCL would also highlight a potential path to increasing the commercial potential of the combination by two to three-fold in comparison to the number of patients with double-refractory HL. https://www.biospace.com/press-releases/affimed-announces-acimtamig-and-allonk-combination-granted-regenerative-medicine-advanced-therapy-rmat-designation-by-the-u-s-food-and-drug-administration-fda
0 · Reply
Latest News on AFMD
No data available.
deathknight
deathknight Dec. 5 at 7:02 PM
$AFMD Heard that this board is closed. Is this why no new post since Tuesday?
2 · Reply
Think_Bigly
Think_Bigly Dec. 5 at 2:10 AM
$AFMD mobile app.
0 · Reply
Think_Bigly
Think_Bigly Dec. 3 at 4:59 AM
$AFMD buying will resurge the day it opens, bcoz the smart trades got out early, and they're looking for an entry. The stock isn't going any lower.. imo.
1 · Reply
SRT2019
SRT2019 Dec. 3 at 4:07 AM
$AFMD Glide has updated Affimed logo on their website.
1 · Reply
Think_Bigly
Think_Bigly Dec. 1 at 1:02 AM
$AFMD RMAT designation will accelerate development and save 'the developer' ~$100M in development costs. https://www.biospace.com/press-releases/affimed-announces-acimtamig-and-allonk-combination-granted-regenerative-medicine-advanced-therapy-rmat-designation-by-the-u-s-food-and-drug-administration-fda
0 · Reply
Think_Bigly
Think_Bigly Nov. 30 at 6:05 PM
$AFMD Timing: buyers will return 30 in days. Generally, a wash sale has three parts. An investor notices they are in a losing position, so they close it by selling the stock or exiting a trading position. The sale allows them to take a loss that they can legally claim on their tax returns as a reduction of their earnings for that year, which reduces their total tax liability. The investor will look to purchase the security at or below the price at which they sold it—if the purchase occurred 30 days before or after the sale, it is considered a wash sale, and the loss cannot be claimed. https://www.investopedia.com/terms/w/washsale.asp
0 · Reply
caradhras36
caradhras36 Nov. 28 at 7:38 PM
$AFMD If there are any plans of changing the fate of this stock by institutions or capital investment firms, I would do it after new year when people sell it for tax loss. I don’t expect anything before new year’s. That’s the game theoretical approach.
0 · Reply
Think_Bigly
Think_Bigly Nov. 27 at 4:39 AM
$AFMD RMAT designation provides several benefits, including all the advantages of the Fast Track and Breakthrough Therapy designations, such as early and frequent interactions with the FDA to facilitate accelerated approval. It allows for accelerated approval based on surrogate or intermediate endpoints—biomarkers that substitute for direct clinical benefits—enabling earlier market access for promising therapies.
0 · Reply
Think_Bigly
Think_Bigly Nov. 27 at 4:26 AM
$AFMD Abstract - In March 2017, the US FDA introduced the new Regenerative Medicine Advanced Therapy (RMAT) designation thus recognizing the enormous potential of these medicines and the need for efficient regulatory tools to accelerate their development and their commercial availability. https://pubmed.ncbi.nlm.nih.gov/29895180/
0 · Reply
Think_Bigly
Think_Bigly Nov. 27 at 12:47 AM
$AFMD Solid tumor market is 2-3x greater than Hodgkins disease. -This promising combination has applicability not only in HL, but also in CD30 positive lymphomas such as peripheral T-cell lymphoma (PTCL), which can also be resistant to conventional therapies, has a high risk of relapse, and where few products are approved. Generating clinical proof-of-concept in PTCL would also highlight a potential path to increasing the commercial potential of the combination by two to three-fold in comparison to the number of patients with double-refractory HL. https://www.biospace.com/press-releases/affimed-announces-acimtamig-and-allonk-combination-granted-regenerative-medicine-advanced-therapy-rmat-designation-by-the-u-s-food-and-drug-administration-fda
0 · Reply
Think_Bigly
Think_Bigly Nov. 27 at 12:41 AM
$AFMD IMO.. Gilde will keep their finger in the dike until this approval comes about.. -Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA) -RMAT designation is intended to expedite the development and review of regenerative medicine therapies, including cell therapies, that aim to address serious or life-threatening conditions. RMAT designation provides the same expedited review benefits as a Breakthrough Therapy Designation, but is exclusively focused on regenerative medicine products. This designation provides Affimed enhanced access to FDA resources including the potential for accelerated approval and priority review. These benefits could significantly reduce the time required to deliver the acimtamig and AlloNK combination to R/R HL patients in need.
0 · Reply
Think_Bigly
Think_Bigly Nov. 26 at 7:20 PM
$AFMD $XBI moving up $122 ish after breaking thru 5 year resistance at 115ish. https://www.inkl.com/news/healthcare-etfs-trounce-tech-grab-billions-as-big-money-flees-bubble-fears
0 · Reply
Sumdumbguy2
Sumdumbguy2 Nov. 26 at 12:41 AM
$AFMD my hypothesis is that we are being baited with crumbs to see if anyone holding will sell for crumbs to try and reduce outstanding shares.
2 · Reply
Morseus01
Morseus01 Nov. 25 at 10:27 PM
$AFMD well back to .05 again would be nice to see above .1 again
1 · Reply
SaintRaw
SaintRaw Nov. 25 at 10:05 PM
$AFMD
0 · Reply
Omarhabibeh
Omarhabibeh Nov. 25 at 9:48 PM
$AFMD nice move, any idea how many shares traded?
2 · Reply
Think_Bigly
Think_Bigly Nov. 25 at 8:48 PM
$AFMD PTCL is 2x to 3x larger market. - PTCL would also highlight a potential path to increasing the commercial potential of the combination by two to three-fold in comparison to the number of patients with double-refractory HL.
0 · Reply
TritiumH3
TritiumH3 Nov. 25 at 8:45 PM
$AFMD I am rich again 🤣
1 · Reply
Think_Bigly
Think_Bigly Nov. 25 at 8:45 PM
$AFMD - CASH flow to NPV - -This promising combination has applicability not only in HL, but also in other CD30 positive lymphomas such as peripheral T-cell lymphoma (PTCL), which can also be resistant to conventional therapies, has a high risk of relapse, and where few products are approved. Generating clinical proof-of-concept in PTCL would also highlight a potential path to increasing the commercial potential of the combination by two to three-fold in comparison to the number of patients with double-refractory HL.
0 · Reply
NOTaPUNDIT
NOTaPUNDIT Nov. 25 at 8:34 PM
$AFMD wow.. +50000% today!!
0 · Reply
Think_Bigly
Think_Bigly Nov. 25 at 8:22 PM
$AFMD .05 ⬆️
0 · Reply
deathknight
deathknight Nov. 25 at 2:43 PM
$AFMD too much nonsense here -- to a point of unnecessary poisonous. Also since there's no update/clarity in sight. I will stay away from the channel until there's something I can share. GLTA. We are all in this together doesn't matter if you are here for days or years -- our shares are all equal.
1 · Reply